Argus analyst David Toung lowered the firm’s price target on Bio-Techne (TECH) to $90 from $95 and keeps a Buy rating on the shares after its Q2 earnings beat earlier this month. The company’s Diagnostics and Spatial Biology segment reported strong demand for molecular diagnostics solutions, including the ExoDx prostate test, the analyst tells investors in a research note. The stock’s “ride may be bumpy”, but Bio-Techne management also expressed optimism about stronger top-line growth and margin expansion in the second half of fiscal 2025, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne expanded menu of RNAscope probes
- Electronic Arts initiated, Workday downgraded: Wall Street’s top analyst calls
- Bio-Techne downgraded to Neutral from Outperform at Baird
- Bio-Techne’s Strong Growth Prospects and Strategic Positioning Drive Buy Rating
- Bio-Techne price target raised to $90 from $88 at Scotiabank